Matches in DBpedia 2016-04 for { ?s ?p "Galapagos NV is a Belgian pharmaceutical research company which was founded in 1999. The company started as a joint venture between Crucell and Tibotec. Currently it has drugs under investigation against rheumatoid arthritis, crohn's disease, ulcerative colitis, psoriasis and systemic lupus erythematosus. The stocks are traded at Euronext Amsterdam under ticker GLPG and at the U.S. OTC market under the ticker symbol GLPYY. The CEO is the Dutchman Onno van de Stolpe."@en }
Showing triples 1 to 4 of
4
with 100 triples per page.
- Galápagos_NV abstract "Galapagos NV is a Belgian pharmaceutical research company which was founded in 1999. The company started as a joint venture between Crucell and Tibotec. Currently it has drugs under investigation against rheumatoid arthritis, crohn's disease, ulcerative colitis, psoriasis and systemic lupus erythematosus. The stocks are traded at Euronext Amsterdam under ticker GLPG and at the U.S. OTC market under the ticker symbol GLPYY. The CEO is the Dutchman Onno van de Stolpe.".
- Q19903276 abstract "Galapagos NV is a Belgian pharmaceutical research company which was founded in 1999. The company started as a joint venture between Crucell and Tibotec. Currently it has drugs under investigation against rheumatoid arthritis, crohn's disease, ulcerative colitis, psoriasis and systemic lupus erythematosus. The stocks are traded at Euronext Amsterdam under ticker GLPG and at the U.S. OTC market under the ticker symbol GLPYY. The CEO is the Dutchman Onno van de Stolpe.".
- Galápagos_NV comment "Galapagos NV is a Belgian pharmaceutical research company which was founded in 1999. The company started as a joint venture between Crucell and Tibotec. Currently it has drugs under investigation against rheumatoid arthritis, crohn's disease, ulcerative colitis, psoriasis and systemic lupus erythematosus. The stocks are traded at Euronext Amsterdam under ticker GLPG and at the U.S. OTC market under the ticker symbol GLPYY. The CEO is the Dutchman Onno van de Stolpe.".
- Q19903276 comment "Galapagos NV is a Belgian pharmaceutical research company which was founded in 1999. The company started as a joint venture between Crucell and Tibotec. Currently it has drugs under investigation against rheumatoid arthritis, crohn's disease, ulcerative colitis, psoriasis and systemic lupus erythematosus. The stocks are traded at Euronext Amsterdam under ticker GLPG and at the U.S. OTC market under the ticker symbol GLPYY. The CEO is the Dutchman Onno van de Stolpe.".